ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is facing a federal securities lawsuit alleging that the company misled investors about the expected timing...

ARS Pharmaceuticals Lawsuit Alleges Investors Were Misled Before SPRY Stock Drop

An update from ARS Pharmaceuticals ( ($SPRY) ) is now available. On July 15, 2026, ARS Pharmaceuticals announced that Board member Richard Lowentha...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRY	$5.85	-5.11%	748.29K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SPRY	$5.85	-5.1%	748.29K
3
4
5
6

SPRY

SPRY

Get ARS Pharmaceuticals, Inc. Data in Excel

Get ARS Pharmaceuticals, Inc. Data in Excel